Clinical trial · Interventional
Natriuretic Peptide Concentrations of B-type (BNP) During Anesthesia in Patients Previously Sensitized to Anthracyclines
Evolution Natriuretic Peptide Concentrations of B-type (BNP) During General Anesthesia Under Propofol and Sevoflurane Association in Patients Previously Sensitized to Anthracyclines. Pilot Study in Patients Operated on for Breast Cancer.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The cardiotoxicity of anthracyclines chemotherapy remains a major problem, despite clinical and echocardiographic monitoring. In the case of treatment for breast cancer, surgery requiring general anesthesia may follow chemotherapy. Although a possible interaction between general anesthetics and anthracyclines on systolic function is only rarely mentioned, some cases of heart failure and / or conduction disturbances peranesthésique were observed in patients treated or previously treated with anthracyclines. The determination of concentration of BNP is a diagnostic tool used in the detection of heart failure and acute coronary syndromes. The question of a possible synergism between cardiotoxic anthracyclines and anesthetic agents arises. Given its minimally invasive nature and its diagnostic value, the BNP assay might thus allow to highlight a possible subclinical deficiency. To our knowledge, there is very little data regarding a possible synergism between cardiotoxic anthracyclines and anesthetic agents.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dosage of B-type natriuretic peptide (NT-proBNP) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- OTHER
- label
- Participants not previously treated with anthracyclines
- description
- No anthracycline treatment in the 6 months prior to inclusion.
- interventionNames
- Other: Dosage of B-type natriuretic peptide (NT-proBNP)
- type
- OTHER
- label
- Participants previously treated with anthracyclines
- interventionNames
- Other: Dosage of B-type natriuretic peptide (NT-proBNP)
Primary outcomes (3)
- measure
- Pre-operative Concentration of NT-proBNP
- timeFrame
- Before breast surgery
- description
- Mean concentration of NT-proBNP measured before surgery.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Women over 18 years with effective contraceptive method (if applicable) * NT-proBNP \<125 pg / ml * ASA 1 or 2, * Breast cancer histologically proven * Mastectomy or lumpectomy * Neoadjuvant chemotherapy with anthracyclines in 6 months or received no chemotherapy with anthracyclines, * Patients who received the briefing and signed the informed consent * Patients affiliated to a social security system. Exclusion Criteria: * Patients for whom the maintenance of general anesthesia does not use halogenated. * Renal impairment: Creatinine clearance \<60 ml / min, * Patients who for reasons psychological, social, family or geographical could not be treated or monitored regularly according to the criteria of the study, patients deprived of liberty or under guardianship. * Presence of a cardiopathy * Pregnant Women
References
Publications (0)
Data not yet available